Application No.: 09/857581

Docket No.: BB1339USPCT

Page 2

Amendments to Specification

Please replace the following paragraphs:

Paragraph beginning on page 39, line 15

Amplification was carried out in two steps. The first amplification reaction was performed using 1 µL of first strand cDNA and primer set one (SEQ ID NO:11 and SEQ ID NO:12) with 30 cycles of 94°C for 30 seconds, 50°C for 30 seconds and 72°C for one minute. A second amplification reaction was done with 1 μL of the resulting product with primer set two (SEQ ID NO:13 and SEQ ID NO:14) and using 30 cycles of 94°C for 30 seconds, 50.5°C for 30 seconds and 72°C for one minute. The resulting PCR sequence was cloned into pCR2.1 using TOPO™ TA Cloning Kit (Invitrogen). Plasmid DNA was purified using QIAFilter cartridges (Qiagen Inc) or Wizard Plus Minipreps DNA Purification System (Promega) following the manufacturer's instructions. Sequence was generated on an ABI Automatic sequencer using dye terminator technology and using a combination of vector and insert-specific primers. Sequence editing was performed using DNAStar (DNASTAR, Inc.). All sequences represent coverage at least two times in both directions. The nucleotide sequence comprising the cDNA insert in clone sugarbeet 1 is shown in SEQ ID NO:47; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:48. The nucleotide sequence comprising the cDNA insert in clone sugarbeet 2 is shown in SEQ ID NO:60[[61]]; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:61.

Paragraph beginning on page 41, line 13:

A consensus sequence was determined by aligning the amino acid sequences of the present invention using the Clustal method of alignment and this sequence is shown in SEQ ID NO:66. Amino acids not conserved are indicated by Xaa. These are:

Xaa₁₀ Phe or Leu Ser or Leu Xaa₁₆ Xaa₂₃ Ser or Thr Xaa₂₅ lle or Lys Lys or Arg Xaa₃₉ Xaa₄₄ Pro or Leu Pro or Leu Xaa₆₀ Xaa₇₃ Leu or His Ser or Tyr Xaa₇₄ Xaa₉₅ Ala or Thr

Xaa ₉₆	Asn or His
Xaa ₁₀₂	Asn or Ser

Xaa₁₁₀ lle, Val, or Thr

Xaa₁₁₂ Arg or His

Xaa₁₁₇ Asn or Ser

Xaa₁₁₈ Ser or Leu

Xaa₁₂₁ Met or Arg

Xaa₁₂₂ Ala or Val

Xaa₁₂₄ Phe or lle

Xaa₁₂₉ Lys or Arg

Xaa₁₄₇ Lys or Glu

Xaa₁₅₉ Leu or Phe

Xaa₁₆₂ Ala or Val

Xaa₁₆₆ Ser or Gly

Xaa₁₇₀ Gln or Arg

Xaa₁₇₅ Val or Leu

Xaa₁₈₃ Ala or Thr

Xaa₁₈₇ Thr or lle

Xaa₁₉₁ Met or Val

Xaa₂₀₉ Phe or Tyr

Xaa₂₁₉ Arg or Trp

Xaa₂₂₃ Tyr or His

Xaa₂₅₃ Gly or Glu

Xaa₂₅₉ Lys or Glu

Xaa₂₆₃ Val or Asp

Xaa₂₆₄ Val, Asp, or Ile

Xaa₂₆₈ Ala or Val

Xaa₂₇₂ Phe or Leu

Xaa₂₈₅ Thr or Met

Xaa₂₉₃ Glu or Asp

Xaa₂₉₂ Glu or Asp

Xaa₂₉₃ Gln or His

Xaa₂₉₄ Thr or Ile

Xaa₂₉₄ Thr, or Ile

Xaa₃₀₁ Phe or Leu

Xaa₃₀₆ Thr or Ile

Xaa₃₁₁ Val or Glu

Xaa₃₁₂ Val or Ala

Application No.: 09/857581

Docket No.: BB1339USPCT Page 4

Xaa₃₂₅ Arg or Lys

Xaa₃₂₈ Gln or Glu

Xaa₃₂₉ Lys or Arg

Xaa₃₃₄ Val or Ala

Xaa₃₄₂ Arg or lle

Xaa₃₇₇ Thr or lle

Xaa₃₈₁ Glu or Gly

Xaa₃₈₅ Tyr, His, or Cys

Xaa₃₈₇ Ile or Thr

Xaa₃₉₃ Val or lle

Xaa₃₉₄ Leu or Pro

Xaa₄₀₂ Arg or Lys

Xaa₄₀₄ Ser or Pro

Xaa₄₁₃ Ser or Phe

Xaa₄₂₂ Glu or Gly

Xaa₄₂₈ Gly or Arg

Xaa₄₂₉ Pro or Leu

Xaa₄₃₅ Gln or Arg

Xaa₄₄₇ Arg or Gly

Xaa₄₅₃ Asn, Ser, or lle

Xaa₄₅₉ Met or Thr, and

Xaa₄₈₅ Asp or Gly

Please replace the sequence listing with the enclosed amended sequence listing.